NCT04790968 is a NA clinical trial of PSMA-PET in Prostatic Neoplasms, sponsored by Norwegian University of Science and Technology.

Who is sponsoring NCT04790968?

NCT04790968 is sponsored by Norwegian University of Science and Technology.

What drugs are being tested in NCT04790968?

Interventions in NCT04790968: PSMA-PET, PSMA-PET/MRI, PSMA-PET/CT.

What condition does NCT04790968 study?

NCT04790968 studies Prostatic Neoplasms, Neoplasm Metastasis.

Is NCT04790968 still recruiting?

NCT04790968 is currently completed. Last updated 15 November 2024.

Last reviewed 2024-11-15 · How we verify

NCT04790968

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients

Completed NA Last updated 15 November 2024

What this trial tests

NA trial testing PSMA-PET in Prostatic Neoplasms in 90 participants. Completed in 30 September 2024.

Timeline

28 April 2021

Primary endpoint
30 September 2024

30 September 2024

Quick facts

Lead sponsor	Norwegian University of Science and Technology
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	90
Start date	28 April 2021
Primary completion	30 September 2024
Estimated completion	30 September 2024
Sites	3 locations across Norway

Drugs / interventions tested

PSMA-PET
PSMA-PET/MRI
PSMA-PET/CT

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Neoplasm Metastasis — all drugs for Neoplasm Metastasis →

Sponsor

Norwegian University of Science and Technology

Who can join

Eligibility, male only, with Prostatic Neoplasms or Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For high-risk prostate cancer patients, detection of lymph node metastases is crucial to ensure optimal treatment. Standard treatment for these patients is radiotherapy or surgery. The surgery involves resection of the prostate and the pelvic lymph nodes. Currently, the most reliable method to confirm lymph node metastases is by histologic examination of the resected lymph nodes. Ideally, one should be able to detect lymph node metastases prior to treatment. Then, the treatment could be better adjusted to each patient. Imaging methods such as prostate specific membrane antigen positron emission tomography (PSMA-PET) can possibly aid the detection of lymph node metastases. In this study, the investigators want to test whether PSMA-PET or a combination of PSMA-PET and MRI (magnetic resonance imaging) can improve staging of lymph nodes before treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluation of magnetic resonance imaging derived synthetic computed tomography for proton therapy planning in prostate cancer.
Fridström KML, Winter RM, Hornik N, Almberg SS, et al · · 2024 · cited 3× · PMID 39253731 · DOI 10.1016/j.phro.2024.100625
The false myth of "iodine allergy" also in nuclear medicine.
Gómez-Perales JL, García-Mendoza A. · · 2021 · cited 2× · PMID 34585268 · DOI 10.1007/s00259-021-05356-6

Verify or expand the search:

Other trials of PSMA-PET

Trials testing the same drug.

NCT03213951 — Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprost · completed

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other Norwegian University of Science and Technology trials

Trials by the same sponsor.

NCT07521891 — Socket-leg Interface Movements in Transtibial Amputees · NA · not yet recruiting
NCT07463001 — Optimization and Testing Effectiveness of a Collaborative Intervention for School Attendance Problems in Norwegian Munic · NA · not yet recruiting
NCT07422597 — Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prost · NA · recruiting
NCT06558851 — The Effect of Systematic Endurance Training in Treatment of Women With Lipedema · NA · active not recruiting
NCT06893874 — A Pragmatic Trial of Machine Prescription for Migraine · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04790968 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Norwegian University of Science and Technology
Last refreshed: 15 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04790968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing